AI-generated summary
The authors report a randomized, triple-blind, placebo-controlled trial of 46 head and neck cancer patients receiving radiotherapy, comparing photobiomodulation with a placebo. Mouth opening decreased less in the photobiomodulation group during radiotherapy, with less muscle pain and grade 1 trismus, though mouth opening did not differ at six months. The authors conclude the therapy was effective in preventing trismus during radiotherapy.
- Participants
- 46
- Who or what was studied
- Patients undergoing IMRT or VMAT radiotherapy for head and neck cancer
- Wavelengths
- 808 nm
- Limits stated in the abstract
- The abstract reports a single-center trial of 46 patients with no mention of long-term benefit beyond six months, and the reported effect on mouth opening did not persist at follow-up.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
To evaluate the effectiveness of photobiomodulation therapy (PBMT) in the prevention of trismus in patients undergoing Intensity-Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT), through a randomized, triple-blind, placebo-controlled clinical trial. A total of 46 patients undergoing radiotherapy (RT) for head and neck cancer (HNC) were included. Patients were equally and randomly allocated to PBMT and PBMT placebo groups and were evaluated daily by measuring mouth opening, pain during mouth opening, and pain on palpation of the masticatory muscles using the Visual Analog Scale (VAS). An extraoral infrared laser (~ 808 nm), power of 0.1 W, energy of 3 J, 30 s (107 J/cm²) per point was used, applied extraorally to the anterior temporalis (AT), masseter (MM), and temporomandibular joints (TMJ), and intraorally to the medial pterygoid muscle (MP). The Food Quality Inventory (ASGP) and quality of life analysis (QoL) (OHIP-14) were also applied. Statistical analysis included Student’s t-test, Mann-Whitney test, and linear regression models (p < 0.05). Patients in the PBMT group showed a significantly smaller reduction in mouth opening during radiotherapy compared to the placebo group (p = 0.005), as well as a lower prevalence of masticatory muscle pain and grade 1 trismus (p = 0.002). No significant differences were observed between the groups regarding the decayed, missing, and filled teeth index (DMFT), the Oral Health Impact Profile-14 (OHIP-14), or the Anderson Symptom and Overall Performance scores (p > 0.05). Mouth opening did not differ between the groups at the six-month follow-up. Photobiomodulation therapy was effective in preventing trismus and masticatory muscle pain during radiotherapy. Clinical Trial RegistrationClinical trial number: RBR-67qxnt9 (registered on 16/04/2025).
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nm
- Power
- 0.1 W
- Total energy
- 3 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Placebo-controlled, Visual analogue scale, Fluence, GRADE, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.